Koyfin Home > Directory > Health Care > LA Jolla Pharma > EBITDA Margin

LA Jolla Pharma EBITDA Margin Chart (LJPC)

LA Jolla Pharma annual/quarterly EBITDA Margin from 2015 to 2020. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • LA Jolla Pharma EBITDA Margin for the quarter ending June 06, 2020 was $-167m a -179.03% increase of 300m year over year
  • LA Jolla Pharma EBITDA Margin for the last 12 months ending June 06, 2020 was $-263m a -126.13% increase of 332m year over year
  • LA Jolla Pharma Annual EBITDA Margin for 2019 was $-441m a -318.70% increase of 1,405m from 2018
  • LA Jolla Pharma Annual EBITDA Margin for 2018 was $-1,846m a -582.74% increase of 10,758m from 2017
  • LA Jolla Pharma Annual EBITDA Margin for 2016 was $-12,604m a 68.76% decrease of -8,666m from 2015
Other Margins & Efficiency Metrics:
  • LA Jolla Pharma Return on Capital % for the quarter ending September 09, 2018 was -55.05 a -69.64% increase of 38.33 year over year
  • LA Jolla Pharma Return on Equity % for the quarter ending September 09, 2018 was -212.92 a 30.37% decrease of -64.67 year over year
View Chart On Koyfin

Quarterly LJPC EBITDA Margin Data

06/2020$-167m
03/2020$-128m
12/2019$-267m
09/2019$-467m
06/2019$-482m
03/2019$-656m
12/2018$-915m
09/2018$-1,360m
06/2018$-3,168m
03/2018$-6,144m

Annual LJPC EBITDA Margin Data

2019$-441m
2018$-1,846m
2016$-12,604m
2015$-3,938m